I met with Dr. Morgans at Northwestern last week for my possible participation in this study. It involves combining Xtandi with a drug referred to as LY2157299. Its in phase II. My MO at Northshore referred me. The research is supported by Johns Hopkins and Eli Lilly. Right now it up to my insurance if I can participate.
Anyone Familiar With a Research Study... - Advanced Prostate...
Advanced Prostate Cancer
I am currently on this trial. The mystery drug is put out by Eli Lilly. I have been on this trial for 3 years. The only side effect is gas, big time.
These links have some information about LY2157299.. It seems that it can sensitize the PC cells to enzalutamide.
Is anyone familiar with Dr. Morgans generally as an oncologist for purposes of being a primary oncologist for a prostate cancer patient?
I seem to have heard her name come up before.
Hi. I met her for the first time last week with my father. I too have seen her name come up as well both on this forum and on-line in general. I am so grateful to Tall Allen which I believe mentioned her name in response to a post I made. We really liked Dr Morgans. I believe she is one of the best in the Chicago Land area specializing in prostate cancer. Maha Hussain I believe is also part of that team and I believe she is a highly respected prostate cancer researcher/pioneer. I also believe that there is an equally respected team at the University of Chicago. We also met Peter Odonnell at U of C and we really liked him as well uchicagomedicine.org/find-a...
I just checked the label on my mystery drug. The LY numbers are different than this study. My bad.
I just saw this trial while researching another MO at Northshore for a 2nd opinion. Did you get in the trial?
Overcoming Drug Resistance in Metastatic Castration-Resitant Prostate Cancer with Novel Combination of TGF-G Recepto Inhibitor LY2157299 and Enzalutamide: A Randomized, Multi-Site Phase II Study
Aims: The purpose is to test the effectiveness and safety of combining enzalutamide with LY2157299 in men with advanced castrate resistant prostate cancer.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH19-186
Sponsor: Johns Hopkins University
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes
I've heard wonderful things about Dr. Shevrin, esp that's he's very kind and empathetic. Far too many doctors have horrible bedside manners, and aren't careful with their words. They can be VERY cruel, creating horrific added stress, which fuels the cancer!!! Sad to say, we've had this happen too often. How a doctor delivers disappointing news can make a HUGE difference to the patients, and their family members.